Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Advances in Posterior Scleral Reinforcement and Scleral Collagen Cross-Linking for the Treatment of High Myopia].

Created on 17 Nov 2026

Authors

Min Yang, Longqian Liu

Published in

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition. Volume 57. Issue 5. Pages 1258-1264. Sep 20, 2026.

Abstract

Myopia, particularly high myopia, has become a major global public health concern. During myopia progression, scleral remodeling is considered a key mechanism underlying axial elongation and is characterized by continuous alterations in scleral tissue structure, extracellular matrix metabolism, and biomechanical properties. Currently, surgical approaches targeting the sclera to control the progression of high myopia can be broadly classified into 2 categories. The first one is posterior scleral reinforcement (PSR), which reinforces the posterior pole of the globe using biological or synthetic materials. The second one is scleral collagen cross-linking (SXL), which enhances the stability of scleral collagen fibers. This review systematically summarizes the mechanisms, materials and surgical approaches, efficacy, and safety of PSR and SXL, with the aim of evaluating the clinical application prospects of sclera-targeted surgical interventions for the treatment of high myopia and informing clinical myopia management.

PMID:
43041580
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement